Consortium for the study of Drug and Herbal & Dietary Supplement-Induced Liver Injury

The Drug-induced liver injury (DILI) is an uncommon and potentially severe adverse drug reaction following an exposure to medications, herbal products or dietary supplements. Idiosyncratic DILI is attributable to medicinal products taken in a therapeutic dose and has been described in association with over 650 drugs used in clinical practice.

The EASL DHILI Consortium is a multidisciplinary network of clinicians, scientists, patients, industry partners, and regulators, all with an interest in the study of Drug and Herbal & Dietary Supplement-induced Liver Injury.

This consortium comes from an awarded COST Action (European Cooperation in Science and Technology , funded by the European Union) called «Prospective European DILI Network CA-17112«